Orogen Royalties Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 137
- Registration Number
- NCT05761444
- Locations
- 🇰🇷
Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu, Korea, Republic of
🇰🇷Inje University Ilsan-Paik Hospital, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷Chonnam National University Hospital, Gwangju, Jeollanam-do, Korea, Republic of
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared with Placebo in Participants Aged 18 to 49 with Moderate to Severe Endometriosis-related Pain
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 380
- Registration Number
- NCT05560646
- Locations
- 🇺🇸
Central Research Associates LLC dba Flourish Research, Birmingham, Alabama, United States
🇺🇸UAB Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸Olympia Clinical Trials, Los Angeles, California, United States
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2007
- Registration Number
- NCT05264506
- Locations
- 🇺🇸
New Phase Research & Development, Knoxville, Tennessee, United States
🇺🇸Alliance for Multispecialty Research, Tempe, Arizona, United States
🇺🇸Universal Axon Clinical Research, LLC, Doral, Florida, United States
A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 498
- Registration Number
- NCT04626596
- Locations
- 🇺🇸
Alabama Clinical Therapeutics (Site 0222), Birmingham, Alabama, United States
🇺🇸Desert Star Family Planning (Site 0193), Phoenix, Arizona, United States
🇺🇸Precision Trials (Site 0187), Phoenix, Arizona, United States
Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)
- Conditions
- Interventions
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 44
- Registration Number
- NCT03885921
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)
- Conditions
- Interventions
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 50
- Registration Number
- NCT03884452
Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 400
- Registration Number
- NCT03882892
Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 313
- Registration Number
- NCT03882047
A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 769
- Registration Number
- NCT03882905
A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 432
- Registration Number
- NCT03882996